A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been report...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Liu, Ningning, Liu, Chunjiao, Li, Xiaofen, Liao, Siyan, Song, Wenbin, Yang, Changshan, Zhao, Chong, Huang, Hongbiao, Guan, Lixia, Zhang, Peiquan, Liu, Shouting, Hua, Xianliang, Chen, Xin, Zhou, Ping, Lan, Xiaoying, Yi, Songgang, Wang, Shunqing, Wang, Xuejun, Dou, Q. Ping, Liu, Jinbao
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4050382/
https://ncbi.nlm.nih.gov/pubmed/24912524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep05240
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים